Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial
- PMID: 15248223
- DOI: 10.1002/art.20299
Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial
Abstract
Objective: To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS).
Methods: This pilot study was a 12-week randomized, double-blind, placebo-controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of etanercept or placebo (vehicle) by twice-weekly subcutaneous injection. Patients met the American-European Consensus Group criteria for SS. The primary outcome required at least 20% improvement from baseline values for at least 2 of the following 3 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes, and IgG level or erythrocyte sedimentation rate (ESR).
Results: Of the 14 patients taking etanercept, 11 had primary SS and 3 had SS secondary to rheumatoid arthritis. Baseline measures did not differ between the 2 groups. Three etanercept-treated patients and 1 placebo-treated patient did not complete the trial. Five etanercept-treated patients and 3 placebo-treated patients showed improvement from baseline in the primary outcome variable at 12 weeks, but the difference was not statistically significant. There were no significant differences between the groups for changes in subjective measures of oral or ocular symptoms (by visual analog scale), the IgG level, Schirmer I test result, van Bijsterveld score, or salivary flow. At 12 weeks, the ESR had decreased in the etanercept group compared with baseline (P = 0.004); however, the mean reduction was only 18.6%.
Conclusion: We found no evidence to suggest that treatment with etanercept at a dosage of 25 mg twice weekly for 12 weeks was clinically efficacious in SS. A larger trial will be necessary to definitively address the efficacy of etanercept in the treatment of SS.
Similar articles
-
Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.Arthritis Rheum. 2004 Aug 15;51(4):601-4. doi: 10.1002/art.20540. Arthritis Rheum. 2004. PMID: 15334433 Clinical Trial.
-
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.Br J Dermatol. 2005 Jun;152(6):1304-12. doi: 10.1111/j.1365-2133.2005.06688.x. Br J Dermatol. 2005. PMID: 15948997 Clinical Trial.
-
Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.J Rheumatol. 2004 Jan;31(1):96-101. J Rheumatol. 2004. PMID: 14705226 Clinical Trial.
-
Antimalarials in Sjögren's syndrome--the Greek experience.Lupus. 1996 Jun;5 Suppl 1:S28-30. Lupus. 1996. PMID: 8803907 Review.
-
Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.BMC Musculoskelet Disord. 2017 May 12;18(1):186. doi: 10.1186/s12891-017-1543-z. BMC Musculoskelet Disord. 2017. PMID: 28499370 Free PMC article. Review.
Cited by
-
AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.Physiol Rep. 2016 Oct;4(19):e12990. doi: 10.14814/phy2.12990. Physiol Rep. 2016. PMID: 27694530 Free PMC article.
-
Treatment of primary Sjögren syndrome.Nat Rev Rheumatol. 2016 Aug;12(8):456-71. doi: 10.1038/nrrheum.2016.100. Epub 2016 Jul 14. Nat Rev Rheumatol. 2016. PMID: 27411907 Review.
-
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272. Ann Rheum Dis. 2004. PMID: 15479866 Free PMC article. Review. No abstract available.
-
Current and future therapies for primary Sjögren syndrome.Nat Rev Rheumatol. 2021 Aug;17(8):475-486. doi: 10.1038/s41584-021-00634-x. Epub 2021 Jun 29. Nat Rev Rheumatol. 2021. PMID: 34188206 Review.
-
Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?PLoS One. 2015 Sep 14;10(9):e0133907. doi: 10.1371/journal.pone.0133907. eCollection 2015. PLoS One. 2015. PMID: 26368934 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous